HRP20070552T3 - Kombinacija antagoniste mglur2 i inhibitora ache za liječenje akutnih i/ili kroničnih neuroloških poremećaja - Google Patents

Kombinacija antagoniste mglur2 i inhibitora ache za liječenje akutnih i/ili kroničnih neuroloških poremećaja

Info

Publication number
HRP20070552T3
HRP20070552T3 HR20070552T HRP20070552T HRP20070552T3 HR P20070552 T3 HRP20070552 T3 HR P20070552T3 HR 20070552 T HR20070552 T HR 20070552T HR P20070552 T HRP20070552 T HR P20070552T HR P20070552 T3 HRP20070552 T3 HR P20070552T3
Authority
HR
Croatia
Prior art keywords
acute
treatment
combination
neurological disorders
chronic neurological
Prior art date
Application number
HR20070552T
Other languages
English (en)
Inventor
Maria Ballard Theresa
Gatti Mcarthur Silvia
Goetschi Erwin
Wichmann Juergen
Johannes Woltering Thomas
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130033&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20070552T3 publication Critical patent/HRP20070552T3/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Primjena inhibitora AChE i antagoniste mGluR2, naznačena time, da je za proizvodnju lijeka za prevenciju ili liječenje akutnog i/ili kroničnog neurološkog poremećaja. Patent sadrži još 12 patentnih zahtjeva.
HR20070552T 2003-07-25 2007-12-06 Kombinacija antagoniste mglur2 i inhibitora ache za liječenje akutnih i/ili kroničnih neuroloških poremećaja HRP20070552T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016968 2003-07-25
PCT/EP2004/008020 WO2005014002A1 (en) 2003-07-25 2004-07-17 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders

Publications (1)

Publication Number Publication Date
HRP20070552T3 true HRP20070552T3 (hr) 2008-05-31

Family

ID=34130033

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070552T HRP20070552T3 (hr) 2003-07-25 2007-12-06 Kombinacija antagoniste mglur2 i inhibitora ache za liječenje akutnih i/ili kroničnih neuroloških poremećaja

Country Status (27)

Country Link
US (1) US7235547B2 (hr)
EP (1) EP1651234B1 (hr)
JP (1) JP5005343B2 (hr)
KR (1) KR100764330B1 (hr)
CN (1) CN1856312A (hr)
AR (1) AR045926A1 (hr)
AT (1) ATE374030T1 (hr)
AU (1) AU2004262897B9 (hr)
BR (1) BRPI0412919A (hr)
CA (1) CA2532347C (hr)
CO (1) CO5640124A2 (hr)
DE (1) DE602004009195T2 (hr)
DK (1) DK1651234T3 (hr)
ES (1) ES2293287T3 (hr)
HR (1) HRP20070552T3 (hr)
IL (1) IL173131A (hr)
MX (1) MXPA06000705A (hr)
MY (1) MY138394A (hr)
NO (1) NO20060328L (hr)
NZ (1) NZ544719A (hr)
PL (1) PL1651234T3 (hr)
PT (1) PT1651234E (hr)
RU (1) RU2357734C2 (hr)
SI (1) SI1651234T1 (hr)
TW (1) TW200524614A (hr)
WO (1) WO2005014002A1 (hr)
ZA (1) ZA200600693B (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2445877B1 (en) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
MX2015004604A (es) 2012-10-23 2015-10-08 Hoffmann La Roche Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
JP2017513844A (ja) 2014-04-23 2017-06-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト
CN112462047B (zh) * 2020-11-13 2023-02-07 北京元恩生物技术有限公司 一种尼卡巴嗪检测试剂盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2002518480A (ja) * 1998-06-22 2002-06-25 ニューロサーチ、アクティーゼルスカブ ５−又は８−ブロモイソキノリン誘導体の製造方法
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
SI1224174T1 (en) * 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
NZ518037A (en) * 1999-10-15 2004-04-30 F Benzodiazepine derivatives useful as metabotropic glutamate receptors
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US6500972B2 (en) * 2001-01-03 2002-12-31 Chinese Petroleim Corp. Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts
US6500955B1 (en) * 2001-02-02 2002-12-31 National Institute Of Pharmaceutical Education And Research One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate
KR100635834B1 (ko) * 2001-04-09 2006-10-18 후지 샤신 필름 가부시기가이샤 아조 화합물 및 이의 제조 방법, 및 아조 화합물의 제조방법에 사용되는 신규 중간체 화합물
NZ528315A (en) * 2001-04-12 2005-04-29 F Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as MGLUR2 antagonists II
EP1379522B1 (en) * 2001-04-12 2005-01-26 F. Hoffmann-La Roche Ag DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
AU2004262897B2 (en) 2009-08-20
DE602004009195T2 (de) 2008-06-26
MY138394A (en) 2009-05-29
US7235547B2 (en) 2007-06-26
SI1651234T1 (sl) 2008-02-29
US20050049243A1 (en) 2005-03-03
AU2004262897B9 (en) 2009-12-17
IL173131A0 (en) 2006-06-11
RU2006105721A (ru) 2007-09-10
JP5005343B2 (ja) 2012-08-22
WO2005014002A1 (en) 2005-02-17
CA2532347C (en) 2012-03-27
IL173131A (en) 2010-12-30
TW200524614A (en) 2005-08-01
EP1651234B1 (en) 2007-09-26
ATE374030T1 (de) 2007-10-15
RU2357734C2 (ru) 2009-06-10
JP2007504096A (ja) 2007-03-01
AR045926A1 (es) 2005-11-16
CO5640124A2 (es) 2006-05-31
DK1651234T3 (da) 2008-01-28
CN1856312A (zh) 2006-11-01
AU2004262897A1 (en) 2005-02-17
PL1651234T3 (pl) 2008-02-29
ZA200600693B (en) 2007-05-30
ES2293287T3 (es) 2008-03-16
PT1651234E (pt) 2007-12-28
DE602004009195D1 (de) 2007-11-08
EP1651234A1 (en) 2006-05-03
MXPA06000705A (es) 2006-04-11
CA2532347A1 (en) 2005-02-17
KR100764330B1 (ko) 2007-10-05
KR20060037404A (ko) 2006-05-03
NZ544719A (en) 2009-04-30
BRPI0412919A (pt) 2006-09-26
NO20060328L (no) 2006-02-17

Similar Documents

Publication Publication Date Title
HRP20070552T3 (hr) Kombinacija antagoniste mglur2 i inhibitora ache za liječenje akutnih i/ili kroničnih neuroloških poremećaja
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
TR201907874T4 (tr) Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
IL169358A (en) A pharmaceutical formulation containing aripiprazole or its metabolite and serotonin reuptake inhibitors for the preparation of a medication to treat mood disorders
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
PA8571501A1 (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
RS54185B1 (en) USE OF 24-ORDER
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
DK1220852T3 (da) Substituerede diazepaner
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
UA94049C2 (ru) Применение ингибиторов glepp-1 для лечения аутоиммунных и/или воспалительных расстройств
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
ME00550B (me) Korišćenje il-18 inhibitora za lećenje ili prevenciju povreda cns
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze